- Home
- FIVE vs RARE Comparison
FIVE vs RARE Comparison
Compare FIVE & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVE
- RARE
- Stock Information
- Founded
- FIVE 2002
- RARE 2010
- Country
- FIVE United States
- RARE United States
- Employees
- FIVE N/A
- RARE N/A
- Industry
- FIVE Department/Specialty Retail Stores
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- FIVE Consumer Discretionary
- RARE Health Care
- Exchange
- FIVE Nasdaq
- RARE Nasdaq
- Market Cap
- FIVE 5.2B
- RARE 4.2B
- IPO Year
- FIVE 2012
- RARE 2014
- Fundamental
- Price
- FIVE $85.92
- RARE $42.59
- Analyst Decision
- FIVE Buy
- RARE Strong Buy
- Analyst Count
- FIVE 21
- RARE 15
- Target Price
- FIVE $126.21
- RARE $93.13
- AVG Volume (30 Days)
- FIVE 1.3M
- RARE 656.5K
- Earning Date
- FIVE 03-19-2025
- RARE 02-13-2025
- Dividend Yield
- FIVE N/A
- RARE N/A
- EPS Growth
- FIVE 0.08
- RARE N/A
- EPS
- FIVE 4.85
- RARE N/A
- Revenue
- FIVE $3,823,378,000.00
- RARE $560,230,000.00
- Revenue This Year
- FIVE $11.23
- RARE $19.26
- Revenue Next Year
- FIVE $10.33
- RARE $36.92
- P/E Ratio
- FIVE $17.70
- RARE N/A
- Revenue Growth
- FIVE 14.32
- RARE 29.01
- 52 Week Low
- FIVE $64.87
- RARE $37.02
- 52 Week High
- FIVE $212.01
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- FIVE 38.73
- RARE 44.76
- Support Level
- FIVE $85.82
- RARE $41.73
- Resistance Level
- FIVE $94.91
- RARE $44.98
- Average True Range (ATR)
- FIVE 3.57
- RARE 1.72
- MACD
- FIVE -0.15
- RARE -0.04
- Stochastic Oscillator
- FIVE 2.67
- RARE 18.03
About FIVE Five Below Inc.
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.